On this page
In short: BPC-157 is a synthetic 15-amino-acid peptide corresponding to a fragment of a protein found in human gastric juice. Two decades of rodent studies report accelerated healing across an unusually wide range of tissues, with proposed mechanisms centring on angiogenesis via VEGFR2, modulation of the nitric oxide system, and FAK–paxillin signalling in connective tissue. Human efficacy data is essentially absent, and most of the literature originates from one research group.
- It is a fragment, not a natural peptide. The 15-residue sequence is a synthetic construct derived from a larger gastric protein; it has not been isolated as a free peptide in the body.
- Gastric stability is the defining property. Unusually for a peptide, it is reported to survive gastric acid — which is why the oral route is even discussed.
- Three mechanisms recur in the literature: VEGFR2-driven angiogenesis, nitric oxide system modulation, and FAK–paxillin signalling in tendon fibroblasts.
- The breadth of reported effects is itself a caution. A compound that helps in gut, tendon, muscle, bone, nerve, cornea and vessel models is either remarkable or under-scrutinised.
- Publication concentration is the central limitation. A large share of the record comes from a single group, with limited independent replication.
What BPC-157 is
BPC-157 is a pentadecapeptide — fifteen amino acids — with the sequence:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
The name stands for Body Protection Compound, and the number is a laboratory designation rather than anything meaningful about the structure. The sequence corresponds to a portion of a larger protein identified in human gastric juice, which is where the "body protection" framing originates: the stomach maintains an environment that would digest most tissue, and the proteins that let it do so without destroying itself were the starting point for the work.
Two points are frequently misstated. First, BPC-157 is not a naturally circulating peptide — it is a synthetic fragment, and the free 15-residue peptide has not been shown to exist as such in the body. Second, it is not related to the growth-hormone peptides it often sits beside in catalogues; it has no known receptor in that family. For where it fits in the wider class, see our guide to research peptides.
Where it came from
The research programme began at the University of Zagreb in the 1990s, led by Predrag Sikirić and colleagues, and grew out of the gastric cytoprotection tradition in gastroenterology — the observation that the stomach lining can be protected against injury by mechanisms independent of acid suppression. The group isolated activity in gastric juice, narrowed it to a protein, and synthesised fragments to find the minimum active sequence. BPC-157 was the fragment that retained activity.
From there the work expanded outward from the gut into an unusually wide range of injury models, and it has continued for roughly thirty years. The compound also entered early-phase clinical evaluation for inflammatory bowel disease under the development designation PL 14736, but no approved product emerged, and no large controlled efficacy trial has been published.
BPC-157's file is deep but narrow in origin. When a body of work comes largely from one group using related models, the appropriate response is neither dismissal nor acceptance — it is to note that independent replication is the missing ingredient, and to weight the findings accordingly.
What the preclinical record covers
The range of models is the first thing that strikes anyone reading this literature. The table below summarises the main areas and what the studies report; every entry is rodent work unless stated.
| Model | What was reported | Depth |
|---|---|---|
| Gastric and duodenal ulcer | Accelerated lesion healing; protection against NSAID- and alcohol-induced damage | |
| Inflammatory bowel models | Reduced lesion severity; fistula closure in several configurations | |
| Tendon transection | Faster functional recovery; improved biomechanical strength of the healing tendon | |
| Ligament and muscle injury | Accelerated healing in crush and transection models | |
| Bone defect | Improved healing in segmental defect models | |
| Peripheral nerve injury | Improved regeneration and functional recovery after transection | |
| Vascular occlusion | Recruitment of collateral pathways; attenuation of downstream syndromes | |
| Corneal and skin wounds | Accelerated epithelial closure | |
| Liver and systemic injury | Attenuation of damage from alcohol and other insults | |
| Human efficacy | No published controlled efficacy trials |
That last row is the one to carry forward. Everything above it describes animals.
Proposed mechanisms
No single receptor has been identified for BPC-157, which is unusual and is part of why the literature reads as a set of converging observations rather than a clean pharmacological story. Four mechanistic threads dominate.
Nitric oxide system modulation
The most consistently reported interaction is with the nitric oxide pathway. Across many of the Zagreb group's studies, BPC-157's effects are examined against L-NAME, a nitric oxide synthase inhibitor, and L-arginine, the substrate for NO production. The recurring finding is that BPC-157 counteracts the consequences of NOS inhibition and appears to modulate NO release rather than simply increasing it — behaving, in the authors' framing, as a regulator of the system in both directions. Since nitric oxide governs vascular tone, platelet behaviour and endothelial function, an agent that stabilises this system would plausibly touch many of the injury models above. The mechanism is best described as consistently observed and incompletely resolved.
VEGFR2 activation and angiogenesis
The most mechanistically specific finding concerns vascular endothelial growth factor receptor 2. Work in endothelial cells reported that BPC-157 increases VEGFR2 expression and activates the receptor — apparently without requiring VEGF itself — with downstream signalling through the Akt–eNOS axis, producing the tube formation and vessel outgrowth characteristic of angiogenesis. This is the thread that ties the disparate models together most economically: new blood vessel formation is rate-limiting for healing in gut, tendon, muscle, bone and nerve alike. It also connects directly back to the nitric oxide observations, since eNOS sits downstream in the same pathway.
FAK–paxillin signalling in tendon and connective tissue
For connective tissue specifically, the proposed mechanism runs through focal adhesion complexes. Studies in cultured tendon fibroblasts reported that BPC-157 increased phosphorylation of focal adhesion kinase (FAK) and paxillin, the signalling proteins that govern how a cell attaches to the extracellular matrix and how it migrates across it. Enhanced tendon fibroblast outgrowth, survival and migration followed. This matters because tendon healing is substantially a problem of getting fibroblasts to the injury site and keeping them there — so a compound acting on focal adhesion turnover is targeting the actual bottleneck rather than a downstream marker. The same group also reported upregulation of growth hormone receptor expression in tendon fibroblasts, which would sensitise those cells to circulating growth hormone.
Gastrointestinal cytoprotection
The original mechanism, and the one with the deepest file. BPC-157 protects gastric mucosa against a range of insults — NSAIDs, alcohol, stress — and the protection does not appear to depend on prostaglandin synthesis, which distinguishes it from conventional cytoprotective agents. Reported contributors include maintained mucosal blood flow (again pointing at the NO and angiogenesis threads), effects on tight junction integrity, and interactions with dopaminergic and serotonergic systems. The gut-level effects are also where the compound's stability matters most, since an orally delivered peptide reaches the gastric mucosa at its highest local concentration before any absorption question arises.
Delivery: injectable versus oral
For most peptides the oral route is a non-starter — digestive proteases cleave the chain and the fragments do not cross the intestinal wall. BPC-157 is discussed differently, and the reason is a specific claimed property.
Why oral is even on the table
BPC-157 is reported to be stable in human gastric juice for extended periods — a durability that follows from its origin in exactly that environment. A peptide that survives gastric acid clears the first hurdle that stops nearly every other peptide from being given orally. Consistent with that, a substantial portion of the rodent literature uses oral administration, typically the compound dissolved in drinking water, and reports effects at sites well beyond the gut.
What the routes actually are
| Route | Use in the literature | What is established |
|---|---|---|
| Intraperitoneal / intramuscular | The majority of rodent injury studies | Most of the tendon, nerve, muscle and vascular findings come from injected administration |
| Oral (in drinking water) | Widely used in the same programme, including for non-gut outcomes | Effects reported at distant sites, implying systemic activity — though absorption was rarely measured directly |
| Topical / local | Corneal, skin and local tissue models | Local application effective in the models tested |
| Human pharmacokinetics | — | Not characterised in published literature for any route |
That last row deserves emphasis, because it is where most online discussion of "oral versus injectable BPC-157" goes wrong. The rodent work supports the claim that orally administered BPC-157 produces effects. It does not establish an oral bioavailability figure, a plasma concentration profile, or a comparison between routes in humans — none of which has been published.
The arginate salt and capsule formats
Research material is supplied in two quite different forms. The acetate salt is the standard lyophilised powder, reconstituted before use — the format nearly all published studies used. BPC-157 arginate is a different salt form, supplied in capsules and promoted specifically for oral stability.
The rationale for the arginate is chemically reasonable: counter-ion choice genuinely affects a peptide's solubility, hygroscopicity and solid-state stability, and arginine brings its own relevance here as the substrate for nitric oxide synthesis. But the honest position is that published head-to-head pharmacokinetic comparisons between arginate and acetate are not available. The claimed advantage rests on formulation reasoning and commercial literature rather than peer-reviewed comparative data. Treat the two as different materials with different handling characteristics, not as an established hierarchy.
Practically: the acetate needs reconstitution — typically with bacteriostatic water — and cold storage thereafter, while the capsule format is a fixed solid presentation. Our peptides vs proteins guide covers why the dry state is so much more stable than solution.
What the evidence does not show
- No human efficacy data. Despite thirty years of work and an early clinical designation, no controlled human efficacy trial has been published.
- Publication concentration. A large share of the literature originates from one group. Citation counts reflect volume, not independent confirmation.
- Breadth cuts both ways. Positive results across almost every tissue tested is unusual, and in a narrow literature it warrants more scepticism, not less.
- No identified receptor. The proposed mechanisms describe pathways it influences, not a binding site it occupies.
- Pharmacokinetics are unpublished. Half-life, distribution and bioavailability in humans are not established for any route.
- Product quality is a real confounder. Analyses of peptides sold online have repeatedly found mislabelled or impure material, which is why lot-level third-party analysis matters before any experiment.
Regulatory status
BPC-157 is not an approved medicine in any jurisdiction, and is supplied strictly as a laboratory reference material. In the United States the FDA placed it in the category of substances it does not permit for pharmacy compounding under section 503A, citing insufficient safety characterisation. It is also prohibited in sport: the World Anti-Doping Agency covers non-approved substances under section S0 of its Prohibited List, banned at all times. Supply for in-vitro and laboratory research, correctly labelled and not marketed for human consumption, sits under a separate framework — consistent with 21 C.F.R. §§ 312.2(b)(3) and 312.160.
BPC-157 is supplied strictly for laboratory and in-vitro research. It is not a medicine, is not for human or veterinary use, and is not intended to diagnose, treat, cure or prevent any disease. Nothing in this article is medical advice or a protocol for administration.
Frequently asked questions
What is BPC-157?
A synthetic peptide of fifteen amino acids corresponding to a fragment of a protein found in human gastric juice. The name stands for Body Protection Compound. It is studied in animal models of tissue injury and is not an approved medicine.
What does the research on BPC-157 show?
Rodent studies report accelerated healing across gut, tendon, ligament, muscle, bone, nerve and vascular injury models. Human efficacy data is absent, and a large share of the literature comes from a single research group, so independent replication remains the main gap.
How does BPC-157 work?
No receptor has been identified. The mechanisms most consistently proposed are modulation of the nitric oxide system, activation of VEGFR2 leading to angiogenesis, FAK–paxillin signalling that promotes fibroblast migration in tendon, and prostaglandin-independent cytoprotection in the gastrointestinal tract.
Is BPC-157 orally active?
It is reported to be stable in gastric juice, and much of the rodent literature used oral administration and still observed effects at distant sites. What has not been published is any human pharmacokinetic data — no oral bioavailability figure or route comparison exists in the peer-reviewed literature.
What is the difference between BPC-157 acetate and arginate?
They are different salt forms of the same peptide. Acetate is the standard lyophilised powder used in nearly all published studies and requires reconstitution. Arginate is supplied in capsules and promoted for oral stability, but published head-to-head pharmacokinetic comparisons between the two are not available.
Is BPC-157 banned in sport?
Yes. As a non-approved substance it falls under section S0 of the WADA Prohibited List and is banned at all times, in and out of competition.
Selected reading
Starting points in the primary literature — each title links to its record on PubMed. These are provided for reference and are not endorsements of any particular finding.
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011.
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 2016.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011.
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014.
- Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 2018.
- Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regeneration Research, 2022.
Continue reading
Every batch is analysed by an independent laboratory for purity and identity, individually lot-tracked, with the full report published before listing.
This article is provided for educational and informational purposes only and is based on published research. Core Labs supplies research chemicals for laboratory use exclusively. Products are not approved for human consumption, nor for medical, veterinary or household use.